# Xenetic Biosciences Reports First Quarter 2026 Financial Results and Highlights Continued Advancement of DNase Oncology Platform
Canonical URL: https://biopharmsignal.com/news/XBIO/xenetic-biosciences-reports-first-quarter-2026-financial-results-and-highlights-continued-advancement-of-dnase-oncology-platform
Ticker: XBIO
Company: Xenetic
Source: Xenetic
Published: 2026-05-13 12:05 EST
Original Source URL: https://ir.xeneticbio.com
## Article Body
No article body is available yet.
## Recent Company News
- 2026-06-04 12:40 EST — [Xenetic Biosciences, Inc. Announces That Its Collaboration Partner Received Approval From the Israeli Ministry of Health to Conduct Exploratory, Investigator Initiated Study of DNase I In Combination With Anti-CD19 CAR T Cells in Large B-Cell Lymphoma](https://biopharmsignal.com/news/XBIO/xenetic-biosciences-inc-announces-that-its-collaboration-partner-received-approval-from-the-israeli-ministry-of-health-to-conduct-exploratory-investigator-initiated-study-of-dnase-i-in-combination-with-anti-cd19-car-t-cells-in-large-b-cell-lymphoma) — Source: Xenetic
- 2026-06-01 13:02 EST — [Xenetic Biosciences Showcases Compelling ASCO 2026 Data Demonstrating DNase I Significantly Enhances CAR-T Cell Persistence, Tumor Control, and Survival](https://biopharmsignal.com/news/XBIO/xenetic-biosciences-showcases-compelling-asco-2026-data-demonstrating-dnase-i-significantly-enhances-car-t-cell-persistence-tumor-control-and-survival) — Source: Xenetic
- 2026-05-13 12:05 EST — [Xenetic Biosciences Reports First Quarter 2026 Financial Results and Highlights Continued Advancement of DNase Oncology Platform](https://biopharmsignal.com/news/XBIO/xenetic-biosciences-reports-first-quarter-2026-financial-results-and-highlights-continued-advancement-of-dnase-oncology-platform) — Source: Xenetic
- 2026-04-22 13:00 EST — [Xenetic Biosciences, Inc. Announces Abstract Acceptance for Presentation at the 2026 ASCO Annual Meeting](https://biopharmsignal.com/news/XBIO/xenetic-biosciences-inc-announces-abstract-acceptance-for-presentation-at-the-2026-asco-annual-meeting) — Source: Xenetic
- 2026-03-13 12:00 EST — [Xenetic Biosciences, Inc. Reports Full Year 2025 Financial Results](https://biopharmsignal.com/news/XBIO/xenetic-biosciences-inc-reports-full-year-2025-financial-results) — Source: Xenetic
## Related News
- 2026-07-21 20:15 EST — BFRG — [BullFrog AI to Participate in Water Tower Research Fireside Chat on Thursday, July 23, 2026](https://biopharmsignal.com/news/BFRG/bullfrog-ai-to-participate-in-water-tower-research-fireside-chat-on-thursday-jul-78357ce8)
- 2026-07-21 20:05 EST — CLPT — [ClearPoint Neuro to Announce Second Quarter 2026 Results August 3, 2026](https://biopharmsignal.com/news/CLPT/clearpoint-neuro-to-announce-second-quarter-2026-results-august-3-2026-6e4f3c05)
- 2026-07-21 20:05 EST — TCMD — [Tactile Medical to Release Second Quarter of Fiscal Year 2026 Financial Results on August 10, 2026](https://biopharmsignal.com/news/TCMD/tactile-medical-to-release-second-quarter-of-fiscal-year-2026-financial-results--798d4004)
- 2026-07-21 20:05 EST — PIII — [P3 Health Partners Schedules Second Quarter 2026 Earnings Release and Conference Call](https://biopharmsignal.com/news/PIII/p3-health-partners-schedules-second-quarter-2026-earnings-release-and-conference-6c9bd8a7)
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)